Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec Stranahan, an analyst at Bank of America Securities, maintained a Hold rating on ...

A man in Johannesburg shared a Senior Java Developer’s payslip, showing a basic salary of a substantial amount The developer, who had seven years of experience, had a salary after deductions that ...

Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...

The funding discussions highlight ongoing investor demand for new and unproven research labs looking to find novel approaches to AI that push the technology forward. Recursive’s goal is to develop ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has reached the initial release candidate (RC) stage. The RC is open for critical bug fixes, with the feature set ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech announced plans to reduce its workforce by approximately 20% as part of a ...

He's mysterious and aspirational, but is he even real? Or is he just a reflection of all of our society? The ‘finance bro’ has become a pretty ubiquitous figure in the American zeitgeist. From ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...